Back to results
US 11,534,489 B2Granted
Anti-PD-L1 antibodies
AssigneeAgency for Science, Technology and Research
InventorsCheng-i Wang, Hsueh Ling Janice Oh, Siok Ping Yeo
Life of this patent
Estimating the term…
Abstract
Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.
Claims9
An isolated nucleic acid encoding an antibody or antigen binding fragment that specifically binds to human PD-L1, comprising:
- (i) a heavy chain variable (VH) region incorporating the following CDRs:
- HC-CDR1 having the amino acid sequence of SEQ ID NO:21
- HC-CDR2 having the amino acid sequence of SEQ ID NO:22
- HC-CDR3 having the amino acid sequence of SEQ ID NO:25;
- and
- (ii) a light chain variable (VL) region incorporating the following CDRs:
- LC-CDR1 having the amino acid sequence of SEQ ID NO:18
- LC-CDR2 having the amino acid sequence of SEQ ID NO:19
- LC-CDR3 having the amino acid sequence of SEQ ID NO:20.
6 more elements
A vector comprising a nucleic acid encoding an antibody or antigen binding fragment that specifically binds to human PD-L1, comprising:
- (i) a heavy chain variable (VH) region incorporating the following CDRs:
- HC-CDR1 having the amino acid sequence of SEQ ID NO:21
- HC-CDR2 having the amino acid sequence of SEQ ID NO:22
- HC-CDR3 having the amino acid sequence of SEQ ID NO:25;
- and
- (ii) a light chain variable (VL) region incorporating the following CDRs:
- LC-CDR1 having the amino acid sequence of SEQ ID NO:18
- LC-CDR2 having the amino acid sequence of SEQ ID NO:19
- LC-CDR3 having the amino acid sequence of SEQ ID NO:20.
6 more elements
Dependencies are inferred from the claim text.